Trials / Unknown
UnknownNCT03505944
Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- Nordic Lymphoma Group · Network
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
Phase I/II trial, with the aim of evaluating the efficacy of venetoclax to the backbone of rituximab-lenalidomide in patients with relapsed/refractory MCL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Venetoclax | venetoclax + lenalidomide + rituximab |
Timeline
- Start date
- 2018-07-01
- Primary completion
- 2022-12-01
- Completion
- 2022-12-01
- First posted
- 2018-04-23
- Last updated
- 2021-10-13
Locations
17 sites across 4 countries: Denmark, Finland, Norway, Sweden
Source: ClinicalTrials.gov record NCT03505944. Inclusion in this directory is not an endorsement.